08:00 , Dec 10, 2012 |  BC Week In Review  |  Company News

RaQualia gastrointestinal news

CJ Group (Seoul, South Korea) has exclusive rights to RaQualia's RQ-00000010 in Korea, China, Taiwan, India and Southeast Asia under a 2011 deal. In 2010, RaQualia granted CJ Group's CJ CheilJedang Co. affiliate exclusive rights...
08:00 , Jan 2, 2012 |  BC Week In Review  |  Company News

RaQualia, Chinese Academy of Sciences, Guangzhou Great Water Tech Co. Ltd. deal

RaQualia signed a letter of intent with the Chinese Academy of Sciences and Guangzhou Great Water Tech to license and/or co-develop RaQualia's RQ-00317076 - a cyclooxygenase-2 inhibitor - for lung cancer and acute pain in...
08:00 , Jan 2, 2012 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

Regulatory milestones Astex Pharmaceuticals Inc. (NASDAQ:ASTX) gained $0.23 (14%) to $1.89 last week after FDA's Oncologic Drugs Advisory Committee scheduled a Feb. 9 meeting to discuss an sNDA from Eisai Co. Ltd. (Tokyo:4523; Osaka:4523) for...
01:31 , Dec 30, 2011 |  BC Extra  |  Company News

RaQualia up on COX-2 inhibitor deal in China

RaQualia Pharma Inc. (JASDAQ:4579) gained Y80 (19%) to Y500 on Thursday after signing a letter of intent with the Chinese Academy of Sciences and Guangzhou Great Water Tech Co. Ltd. (Guangzhou, China) to license and/or...